Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discov…
Biotechnology
US, Salt Lake City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Recursion Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | - | -1.190 | - | 12 | - | -247 | - | -12 | - | -12 | - | 70 |
| 2022 | -1.0500 | -1.407 | 10 | 48 | -178 | -292 | -174 | -48 | -191 | -48 | 57 | 277 |
| 2023 | -1.3600 | -1.649 | 39 | 52 | -239 | -344 | -227 | -52 | -245 | -52 | 81 | 300 |
| 2024 | -1.5800 | -1.541 | 44 | 64 | -328 | -322 | -299 | -64 | -350 | -64 | 110 | 372 |
| 2025 | - | -1.659 | - | 79 | - | -345 | - | -79 | - | -79 | - | 454 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |